Clinical outcomes of early-stage breast cancer in Morocco: A cohort of 400 women

Table 5 Univariate and multivariate analyses of prognostic factors on disease-free survival in women with early-stage breast cancer (n = 400)

Factors		Participants	Hazard ratio (univariable)	Hazard ratio (multivariable)
Age (year)	≥ 40	282 (75.2)	-	-
	< 40	93 (24.8)	1.01 (0.62-1.66, P = 0.964)	1.18 (0.71-1.96, P = 0.530)
Grade (SBR)	1-2	268 (71.5)	-	-
	3	107 (28.5)	1.28 (0.80-2.04, P = 0.301)	1.15 (0.71-1.88, P = 0.563)
Histology	IDC	355 (94.7)	-	-
	ILC	20 (5.3)	1.25 (0.50-3.08, P = 0.632)	1.27 (0.50-3.21, P = 0.611)
Hormone receptor	HR-	94 (25.1)	-	-
	HR+	281 (74.9)	0.76 (0.48-1.22, P = 0.262)	0.80 (0.49-1.31, P = 0.378)
pT	pT2-3	111 (29.6)	-	-
	pT1-2	264 (70.4)	0.56 (0.36-0.88, P = 0.012)	0.76 (0.46-1.25, P = 0.285)
pN	pN+	288 (76.8)	-	-
	pN0	87 (23.2)	0.46 (0.24-0.86, P = 0.016)	0.66 (0.30-1.44, P = 0.298)
Stage	Stage 3	208 (55.5)	-	-
	Stage 1-2	167 (44.5)	0.41 (0.25-0.67, P < 0.001)	0.51 (0.27-0.97, P = 0.041)
Treatment	CMF	142 (37.9)	-	-
	Anthra	233 (62.1)	0.63 (0.41-0.98, P = 0.040)	0.56 (0.36-0.86, P = 0.009)

CMF: Cyclophosphamide, methotrexate, fluorouracil; HR: Hormone receptor; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; pT: Pathological tumor stage; pN: Pathological lymph node stage; SBR: Scarf-Bloom-Richardson.